Catalan parliament defies Madrid pressure, works on independence declaration
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/31/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Upside Options Positioning in AstraZeneca (AZN) Continues -Susquehanna
October 9, 2017 2:36 PM EDTSusquehanna options strategist Alison Edwards notes upside positioning in AstraZeneca (NYSE: AZN), as an opening investor bought 5k April 35 Calls for $1.80, following recent upside positioning via Dec 32.5, 35 & 37.5 Calls,
... MoreAstraZeneca (AZN) Granted Breakthrough Therapy Designation by U.S. FDA for Tagrisso (Osimertinib)
October 9, 2017 9:19 AM EDTAstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for TAGRISSO® (osimertinib) for the 1st-line treatment of patients with metastatic epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: The Breakthrough Designation acknowledges not only TAGRISSOs potential as a 1st-line standard of care in advanced EGFR mutation-positive NSCLC, but also the significant need for improved clinical outcomes in this disease. The results of the FLAURA trial have the potential to redefine clinical... More
